Search

Nifuroxazide

Duloxetine

Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. … [A178741] Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder.

Venlafaxine

Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). … [A252065] Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years.

Diazepam

This current development is subsequently an important addition to the rescue therapy tool chest for patients with epilepsy [L5200]. … It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal

Bromocriptine

Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. … Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity.

Enalapril

It was developed from a targeted research programmed using molecular modelling. … It is also found in a combination product containing [hydrochlorothiazide] that is used for the management of hypertension.

Roxithromycin

It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections. … Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to [erythromycin], [azithromycin], or [clarithromycin].

Doxazosin

Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. … [A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285]

Anagrelide

[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.

Diltiazem

[T28] Being a potent vasodilator, diltiazem is used clinically as an antihypertensive, anti-arrhythmic, and as an anti-anginal agent [L6289] for the management of cardiovascular conditions such as hypertension … Diltiazem is a benzothiazepine derivative with antihypertensive and vasodilating properties.